Since the cloning of the TSH receptor (TSH-R), the target autoantigen of Graves' disease, the receptor 
INTRODUCTION
Thyroid-stimulating hormone (thyrotrophin, TSH) regulates the activity of the thyroid gland. Stimula¬ tion of the gland by TSH occurs on binding of the hormone to thyroid follicular cell plasma membrane TSH receptors (TSH-R). The activation of the TSH-R is coupled to the enhancement of the adenyl cyclase-and protein kinase A-dependent phosphatidylinositol pathway, leading to the synthesis of thy¬ roid hormones and growth of thyroid cells (Laurent el al. 1987 ).
The thyroid gland is also one of the most common targets for organ-specific autoimmune reactivity in man. High-titre autoantibodies to a number of thyroid-specific proteins are known to be present in patients with autoimmune thyroid disease . In Graves' disease and idiopathic myxoedema, autoantibodies to the TSH-R are present which are pathogenic and directly respon¬ sible for disease activity (McGregor, 1990) . Some (Zakarija & McKenzie, 1987) . Anti¬ bodies of both specificities may occur in the same patient, although the precise levels in the serum have yet to be determined. The potency of thyroidstimulating antibodies, like that of TSH, is demon¬ strated by their ability to stimulate cyclic AMP (cAMP) levels, as well as mRNA synthesis for a number of proteins, on incubation with thyroid cells in vitro (Kung et al. 1988; Collison et al. 1991) . The presence and potency of TSH-binding inhibitory immunoglobulins are best determined by a radioreceptor assay (Southgate et al. 1984) . Transfer of these IgG antibodies across the placenta can also lead to transient neonatal hyper-or hypothyroidism, with the duration of the disease being determined by the maternal half-life of IgG in the neonatal circula¬ tion, giving further confirmatory evidence of the pathogenic nature of these antibodies (McKenzie, 1964) .
A better understanding of the TSH-R antigen of Graves' disease will allow mapping of the autoantibody-binding sites responsible for hyperthyroidism and hypothyroidism, together with the important determinants for high affinity binding of TSH. The very low expression of TSH-R on thyroid cells, esti¬ mated at 10 to 10 receptors per cell, has hindered studies on the biochemical purification of the recep¬ tor molecule (Rees Smith et al. 1988; . The availibility of purified receptor protein would allow the establishment of sensitive diagnostic assays for the identification and monitor¬ ing of this group of patients during therapy for their disease.
The recent cloning of the TSH-R from a number of species shows the receptor to be a typical G-binding protein Nagayama et al. 1989; Parmentier et al. 1989; Akamizu et al. 1990a; Frazier et al. 1990; Misrahi et al. 1990 ). The human TSH-R is comprised of 764 amino acids, containing a large amino terminal, an extracellular domain of 395 residues and a signal peptide, together with the remaining residues forming the seven transmembrane regions of G-binding proteins and a short intracellular tail. The large extracellular domain is the region most probably implicated in the binding of TSH and autoantibodies. The essential regions on the TSH-R polypeptide responsible for binding TSH and autoantibodies appear to be critically dependent on the tertiary three-dimensional conformational structure of the molecule or other posttranslational modifications such as glycosylation or phosphorylation, since denatured bacterial receptor protein generated in Escherichia coli failed to bind any of these ligands (Huang et al. 1992) . Six N-linked glycosylation sites are predicted in the extracellular region and recent in-vitro mutagenesis studies suggest that at least two of these sites appear to be essential for binding TSH to the recombinant receptor (Russo et al. 1991a ).
Expression of TSH-R in a number of different eukaryotic cells has shown that the recombinant receptor responds to TSH and thyroid-stimulating antibodies in terms of cAMP activity Nagayama et al. 1989; Akamizu et al. 1990a; Frazier et al. 1990; Misrahi et al. 1990; Harfst et al. 1992a ). However, the levels of recombinant TSH-R expressed in these eukaryotic cells have been just marginally higher than those found in thyroid cells, with the consequence that it has not allowed purifi¬ cation of the receptor molecule from these sources.
We now report our studies on the expression and purification in milligram quantities of the receptor protein in insect cells using recombinant baculoviruses, and show the usefulness of the proteinpurified receptor molecule in measuring autoanti¬ bodies in the sera of patients with Graves' disease. Unlike other mammalian G-protein-coupled recep¬ tors which have been expressed in high levels in insect cells (Parker et al. 1991; Reilander et al. 1991; Vasudevan et al. 1991) , this expression system is unsuitable, for some unknown reason, for the expression of the full-length TSH-R. It is, however, superior in the expression of substantial quantities of the truncated extracellular region of the receptor. Access to this material will permit immunological investigations of the role of the TSH-R in Graves' disease.
MATERIALS AND METHODS
Recombinant bacterial TSH-R(E) fusion protein The extracellular region of the human TSH-R (TSH-R(E)), encoding amino acids 21-414, was produced as a fusion protein with glutathione S-transferase (GST) in the vector pGEX-2T and purified from the inclusion bodies by preparative gel electrophoresis (Huang et al. 1992 (BSA) in PBS-Tween for 1 h at room temperature. ELISA was performed using neat hybridoma supernatants or serial dilutions of ascitic fluids as described previously (Ewins et al. 1992) .
ELISA with insect cell-produced immunoaffinitypurified TSH-R(E) protein This was performed as described above, except that each well was coated with 150 |il purified receptor protein at 2 Ug/ml and the blocking step performed with 2% BSA in PBS. After washing the wells with PBS-Tween, 150 (tl ammonium sulphateprecipitated immunoglobulin from patients with Graves' disease, at serial dilutions of 1:10, 1:25 and 1: 50 (in PBS-Tween), were added and incubated at room temperature for 2 h. Precipitated IgGs from normal pooled serum lacking thyroid-stimulating or -blocking antibody (Collison et (Page, 1989; Page et al. 1989 ). The orientation of the cDNA was confirmed by digestion with EcoRV and PstI. The recombinant vectors were subjected to DNA sequencing to verify the precision of the PCR amplification and the identity of the TSH-R(E)-amplified cDNA, using the sequencing primers and Sequenase (USB, Cleveland, OH, U.S.A.) as described previously (Huang et al. 1992) . Approxi¬ mately 800 bp of the 1200 bp cDNA of TSH-R(E) was sequenced in both strands and found to be ident¬ ical to the published sequence (Nagayama et ). For Southern blotting, the DNA was digested with BamHI and, after electrophoresis and transfer, hybridized with labelled TSH-R(E) cDNA probe (Huang et al. 1992 ). For Northern blotting, total RNA was extracted from the insect cell monolayer cultures growing in 3 cm Petri dishes, which had been post-infected with recombinant baculovirus at 24, 30, 44, 48 and 60 h, using the single-step guanidium thiocyanate method (Huang et al. 1990 ). Northern blotting was performed using a labelled TSH-R(E) cDNA probe (Huang et al. 1992 washed twice in warm TCI00 medium without methionine and cultured at 27°C for 1 h. The medium was discarded and fresh TCI00 medium lacking methionine was added (0-3 ml) followed by 50 |iCi 35S translabel (ICN, High Wycombe, Bucks, U.K.) and cultured for an additional 4 h at 27°C. At the end of the incubation, the labelled medium was removed and the cells were harvested and lysed in 300 pi ice-cold 25 mM Tris-HCl, pH 7-4, 0-15 m NaCl, 5 mM EDTA, 1% (v/v) Triton X-100 contain¬ ing a cocktail of proteolytic inhibitors (100 (ig phenylmethylsulphonylfluoride/ml, 100 (ig aprotinin/ml, 10 (ig leupeptin/ml and 10 pg pepstatin/ml) (lysis buffer). The lysed extract (300 pi) was precleared by mixing with 30 pi (bed volume) protein G-Sepharose for 1 h. For immunoprecipitation, 100 pi precleared extract were mixed with 1 pg puri¬ fied KCHM A7 antibody and left to mix for 2 h at room temperature. After several washes with lysis buffer, the bound labelled proteins were eluted in 125 mM Tris-HCl buffer, pH 6-8, containing 10% glycerol, 2% sodium dodecyl sulphate (SDS), 1% 2-mercaptoethanol and bromophenol blue. After electrophoresis in 10% SDS-polyacrylamide gel, the gels were fixed and treated with En Hance (DuPont, Stevenage, Herts, U.K.) and exposed for autoradiography using Cronex lightning screens (DuPont) at -70°C. The specificity of the immunoprecipitate was further confirmed by premixing the antibody with 60 pg bacterial inclusion bodies (20 mg/ml) of GST-TSH-R(E) fusion protein or an irrelevant GST-thyroid peroxidase fusion protein ), prior to the addition of the precleared labelled lysate.
Extraction of TSH-R(E) from recombinant baculovirus-infected insect cells
Two different methods were used for extraction. In the first, High Five monolayer cells infected with p36C-TSH-R(E) (MOI = 5) were harvested from three T-175 flasks at 48 h after infection, pooled and washed in PBS by centrifugation at 1200¿» for 5 min. To the washed pelleted cells (approximately 100-120 x 10 cells) were added 6 ml ice-cold lysis buffer, and the cells were left on ice with occasional gentle stirring for 30 min. After centrifugation at 1200 g for 10 min, the supernatant was removed and saved on ice whilst the nuclear and unlysed cell pellet was reextracted with 3 ml fresh lysis buffer, as described above. The supernatants were pooled and referred to as solubilized cytosolic/membrane protein, whilst the pellets were described as unsolubilized pellets. This material or the solubilized cytosolic/membrane protein used for immunoaffinity purification of TSH-R(E) protein was used for immunoblotting following SDS-polyacrylamide gel electrophoresis (PAGE). Immunoblotting was performed using " Ilabelled affinity-purified rabbit anti-mouse IgG and autoradiography (Ewins et al. 1992 ).
In the second method, crude microsomal mem¬ branes were prepared from the insect cells by har¬ vesting as described above and disruption by freezethaw lysis. Briefly, the pelleted cells were recovered from -70°C , 3 ml ice-cold 10 mM Tris-HC1, pH 8-3, 0-15 M NaCl, containing the cocktail of proteolytic inhibitors, were added and the cells were allowed to thaw slowly on ice. After gentle mixing with a 1 ml pipette, the disrupted cells were centri¬ fuged at 1200^f or 10 min at 4°C , the supernatant was saved and the pellet subjected to another round of freeze-thaw lysis. The supernatants were pooled and solubilized in the above buffer, containing 1% (w/v) sodium deoxycholate, for immunoaffinity purification of TSH-R(E) protein.
Immunoaffinity purification of recombinant TSH-R(E) protein from insect cell cultures Immunoglobulin from ammonium sulphate (40%)-precipitated ascitic fluid was coupled to CNBractivated Sepharose at 10 mg antibody/ml gel (Ewins et al. 1992) . Ultracentrifuged solubilized insect cell lysate was passed through a 2 ml ovalbuminSepharose (10 mg protein/ml gel) column to remove non-specific binding proteins before passage through a 5 ml (bed volume) KCHM A7-Sepharose column. The column was washed with 3 bed vols Tris/saline/0-5% Triton X-100 buffer before elution with 50 mM diethylamine buffer, pHll-5, and extensive dialysis in PBS containing 003% deoxycholate.
Deglycosylation Affinity-purified TSH-R(E) (24 pg protein) was denatured in 1% (w/v) SDS and 1% (v/v) 2-mercaptoethanol by placing in boiling water for 3 min. After dilution with 10 vols 20 mM potassium phosphate, 10 mM EDTA, pH 7-4, containing 1% (w/v) Nonidet P-40 (NP40), half the sample was treated with 0-5 U endoglycosidase F/endopeptidase F (Boehringer, Southampton, Hants, U.K.), while the enzyme was omitted in the second tube, and the samples were incubated at 37°C for 20 h. The pro¬ teins were electrophoresed and detected by immunoblotting.
Absorption of Graves' disease autoantibodies Seven precipitated immunoglobulins from the 13 sera used in this study (patients 2, 3, 6, 9, 19, 20 and 21) were absorbed on Triton X-100 extracts of insect cell-produced TSH-R(E) protein or wild-type virus-infected cell lysate by mixing with 200 pi ultracentrifuged extract at 7°C for 16 h. After microfuge centrifugation, the extracts were assessed in duplicate tubes for residual receptor-blocking autoantibodies, using TRAK assay kits (Huang et al. 1992 ).
Assessment of TSH binding to TSH-R(E)
The binding of I-labelled TSH to the insect cells producing TSH-R(E) was performed using a modi¬ fication of the method described previously (Huang et al. 1992 ), using the TRAK assay kit. All incuba¬ tions were at room temperature. A previously deter¬ mined limiting amount of I-labelled TSH from the kit (100 pi) was mixed with 240 pi (5 mg/ml) ultracentrifuged, Triton X-100 (1%) extract of insect cells producing TSH-R(E) or with a lysate from wild-type virus-infected cells (4-6 mg/ml) and left to incubate for 1 h. After centrifugation on a microfuge for 10 min, each supernatant was divided equally between two tubes; this was followed by the addition of 50 pi porcine thyroid membranes and 15 pi zero standard sera from the kit and incubation for 2 h.
After precipitation with ice-cold polyethylene glycol (PEG) solution (from the kit) and centrifugation, the supernatants were discarded, the pellets counted for residual activity and the results calculated in terms of percentage specific inhibition of I-labelled TSH binding.
RESULTS
Characterization of a monoclonal antibody to the bacterial TSH-R(E) fusion protein
Immunization of the mice with the recombinant bacterial GST-TSH-R(E) fusion protein produced (Fig. 2) (Fig. 3, lane 2) , which were absent in immunoprecipitates from wild-type infected cells (Fig. 3, lane 6) . The speci¬ ficity of the immunoprecipitation was confirmed when bacterial GST-TSH-R(E) fusion protein, mixed with KCHM A7 prior to immuno¬ precipitation with labelled infected Sf21(SD) cells, blocked the ability of the antibody to precipitate the two polypeptide bands (Fig. 3, lane 4) ; an irrelevant GST-thyroid peroxidase fusion protein ) still allowed the antibody to immunoprecipitate the 63 and 49 kDa proteins (Fig. 3, lane 3) . As expected, there was no difference in the pattern of immunoprecipitation in wild-type virus-infected insect cells upon the addition of these inclusion bodies (Fig. 3, lanes 7 and 8) (Fig. 6) (Fig. 7a, lane 3 (Fig. 7a, lane 3 TSH-blocking antibodies could be measured by this procedure, using dilutions of 1:10, 1:25 and 1:50 (Fig. 9) . The specificity of autoantibody binding to purified receptor by ELISA was confirmed by absorption experiments on the recombinant TSH-R(E). Lysates from receptor-expressing insect cells were capable of absorbing the autoantibodies, lead¬ ing to a significant reduction in their receptorblocking activity when measured in the TRAK assay kit (Fig. 10a) . (Luckow & Summers, 1988; Page & Murphy, 1990) . It is especially suited for high level expression of membrane-associated transmembrane proteins such as the ß-adrenergic receptor (Parker et al. 1991; Reilander et al. 1991) , muscarinic receptor , epidermal growth factor (EGF) receptor (Greenfield et al. 1988 (Greenfield et al. , 1989 , growth hormone receptor (Ota et al. 1991) , insulin receptor (Sissom & Ellis, 1989; Paul et al. 1990 ) and various 12-transmembrane region transporter and channel proteins (Fafournoux ei al. 1991; Li et al. 1992) . (Miller, 1988 (Akamizu et al. 19906) . It is therefore likely that the 45 kDa protein in the affinity-purified receptor preparations is actin. Our experience of the purification of the TSH-R(E) has also demonstrated the extreme susceptibility of this molecule to proteolytic degradation (Russo et al. 19916, 1992) (Harfst et al. 1992a) .
A number of investigators have used various syn¬ thetic peptides derived from different regions of the TSH-R sequence to examine the binding of auto¬ antibodies . It is apparent that both TSH and autoantibodies recog¬ nize conformation-dependent regions on the TSH-R molecule (Huang et al. 1992 (Frazier et al. 1990; Braun et al. 1991) , and it will be interesting to determine the effect of truncations at various loca¬ tions in the transmembrane regions of the receptor on high affinity binding of the hormone.
The availability of substantial quantities of a trun¬ cated TSH-R protein will allow a number of impor¬ tant issues regarding the role of this receptor in Graves' disease to be addressed. Thus a battery of monoclonal antibodies can be generated to the sur¬ face of the native receptor protein (Loosefelt et 
